Italia markets closed

PRTG Jul 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,05000,0000 (0,00%)
In data: 10:59AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,4100
Denaro0,0000
Domanda0,7500
Prezzo d'esercizio2,50
Scadenza2024-07-19
Min-Max giorno0,0500 - 0,4100
Contratto - Min-MaxN/D
Volume1
Open Interest1
  • GlobeNewswire

    Portage Biotech Announces $6.0 Million Registered Direct Offering

    WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.90 per share (or common stock equ

  • GlobeNewswire

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY. The Portage management team will participate in one-on-one investor meetings du

  • GlobeNewswire

    Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

    WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-